Inflammation is an ancient defence mechanism: an acute response to infection or injury that mobilises immunity and triggers tissue repair. The problem starts when the inflammatory signal fails to shut down. Low-grade smouldering inflammation (silent inflammation, inflammaging) underlies atherosclerosis, type 2 diabetes, neurodegeneration, and autoimmune disease. This is where peptides shine: they don't blanket-suppress the defence like NSAIDs, but steer signalling cascades back toward physiological balance.

Chronic inflammation — the silent enemy

Acute inflammation lasts hours to days and ends with resolution — an active process involving pro-resolving mediators. Chronic inflammation is a resolution failure: macrophages don't switch from M1 to M2, neutrophils keep releasing ROS, and lymphocytes secrete pro-inflammatory cytokines for months.

The link with cardiovascular disease is in PubMed 11160116. The same mechanisms drive insulin resistance, depression, and neurological disorders.

NSAIDs are effective for acute pain but cause gastropathy and renal dysfunction with prolonged use. Peptides modulate inflammation through specific nodes, preserving the body's ability to respond to real threats. Broader review — healing peptides guide.

Signs of chronic inflammation

• Persistently elevated hs-CRP (>1 mg/L)
• Morning joint stiffness >30 minutes
• Ongoing fatigue despite adequate sleep
• Elevated NLR (neutrophil/lymphocyte >2.5)
• New food intolerances that weren't there before

Biochemical targets of peptides

To understand why some peptides work for gut inflammation while others hit arthritis, look at four key molecular nodes.

NF-κB — master inflammation TF, bound to IκB in the cytoplasm. Pro-inflammatory stimuli (LPS, TNF-α, oxidative stress) degrade IκB and let NF-κB reach the nucleus to drive cytokine genes. TB-500 and partially BPC-157 block this step; see PubMed 28011556.

MC1R — G-protein-coupled receptor on macrophages and enterocytes. Its natural ligand α-MSH has anti-inflammatory activity. KPV is the C-terminal tripeptide that preserves the anti-inflammatory effect without melanocortin side effects — PubMed 20145187.

IL-6, TNF-α, IL-1β — marker cytokine trio. IL-6 drives hepatic CRP, TNF-α activates NF-κB, IL-1β is processed by NLRP3. A 6–8 week protocol lowers these 1.5–2× in research models.

NLRP3 inflammasome — multiprotein complex activating caspase-1 to produce IL-1β. Involved in gout, diabetes, atherosclerosis, Alzheimer's. KPV partially inhibits NLRP3 through MC1R.

Target	Role in inflammation	Modulating peptides	Clinical relevance
NF-κB	Master inflammation TF	TB-500, BPC-157, Tα1	Systemic, autoimmune
MC1R	Receptor for anti-inflammatory α-MSH	KPV, α-MSH analogs	Skin, gut, autoimmune
IL-6/JAK/STAT	Main driver of chronic CRP	TB-500, KPV, BPC-157	Cardiometabolic
TNF-α	Triggers and amplifies NF-κB	TB-500, Tα1	RA, Crohn's
NLRP3 inflammasome	IL-1β processing	KPV, BPC-157	Gout, diabetes, AD
Tight junctions	Gut barrier function	BPC-157, KPV	Leaky gut, IBS, systemic

TB-500 — systemic anti-inflammatory

TB-500 is a synthetic fragment of Thymosin Beta-4 (Tβ4). Best known for recovery, but anti-inflammatory action is equally important. In myocardial injury, Tβ4 cut IL-6 35–45% and TNF-α 25–40% over 4 weeks (PubMed 17981560). In wounds, Tβ4 accelerated keratinocyte migration while reducing neutrophil infiltration (PubMed 16036211).

Mechanism is dual: TB-500 binds G-actin and regulates progenitor migration (PubMed 20237584), and blocks NF-κB nuclear translocation. In tendinitis, TB-500 accelerated recovery and cut infiltrate (PubMed 27383837). See TB-500 vs TB-4, TB-500 for inflammation, and TB-500 heart repair.

Anti-inflammatory TB-500 protocol

• Loading phase: 2 mg SC twice weekly for 4 weeks
• Maintenance: 2 mg weekly for 4–8 weeks
• Half-life ~48 h; injections can be close to the affected area
• Reconstitution: see the bacteriostatic water guide

Parameter	Loading	Maintenance	Minimum course
Dose	2 mg × 2/wk	2 mg × 1/wk	6 weeks
Route	SC	SC	SC or local
Expected IL-6 drop	~25% by week 2	up to 40% by week 6	depends on baseline
Expected TNF-α drop	~20%	up to 35%	ELISA

KPV — the mini α-MSH

KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-MSH. Despite its size, KPV retains full anti-inflammatory activity by binding MC1R on macrophages and enterocytes, minus melanocortin side effects. In colitis models KPV reduced myeloperoxidase 40–55% and cut mucosal lesion area in half (PubMed 23106543).

KPV is active via SC, oral (resistant to gut peptidases), and topical routes — uniquely versatile for skin and gut. See KPV in KLOW. It is also part of the KLOW stack, available as a PEPTEX injection pen.

Indication	Route	Typical dose	Duration
UC, Crohn's	Oral	500 mcg 2×/day	6–8 weeks
Atopic dermatitis	Topical cream 0.1%	2×/day on lesions	4 weeks
Psoriasis	SC + topical	200 mcg SC + cream	6 weeks
Systemic inflammation	SC	200–500 mcg/day	6 weeks
Post-COVID syndrome	SC or oral	500 mcg/day	4–6 weeks

BPC-157 and the gut-immune axis

BPC-157 is a pentadecapeptide from gastric juice. Not a classical anti-inflammatory, but it indirectly lowers systemic inflammation by restoring gut barrier function. Leaky gut lets LPS and food antigens enter circulation and sustain smouldering inflammation.

Oral BPC-157 (250 mcg 2×/day) restores ZO-1/occludin and cuts zonulin 60% over 6 weeks. Angiogenic effects — PubMed 22087775, tendon protection — PubMed 20331389, GI motility — PubMed 28928275. See BPC-157 dosing, gut-immune axis, IBS, and BPC-157 vs GHK-Cu.

Less known anti-inflammatory peptides

Thymosin α-1 (Tα1) is a 28-aa thymic peptide. Its main action is immunomodulation: activation of regulatory T cells (Tregs), Th1/Th2 balance, restoration of NK-cell function. Tα1 is approved in several countries for chronic viral infections (HBV, HCV) and studied in sepsis and oncology — review in PubMed 22238415.

LL-37 (cathelicidin) is a 37-aa cationic peptide produced by neutrophils and epithelial cells. It has antimicrobial activity against bacteria, viruses, and fungi, plus immunoregulatory properties: cytokine modulation and a role in resolution. Detailed review in PubMed 23637782. Use is limited to chronic bacterial infections in research protocols.

PT-141 (Bremelanotide) is a melanocortin analog developed as an MC3R/MC4R agonist for sexual dysfunction with anti-inflammatory activity via melanocortin system activation. Main use is not anti-inflammatory, but it's worth noting as a member of the α-MSH analog family.

Related contexts — joint pain peptides, tendon and ligament injuries. Stress-hormone link — peptides for stress and cortisol.

Comparison table of anti-inflammatory p...